Holen Sie sich die Stockscreener-App
4.33
2.70%
-0.12
Schlusskurs vom Vortag:
$4.45
Offen:
$4.49
24-Stunden-Volumen:
433.38K
Relative Volume:
0.40
Marktkapitalisierung:
$295.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-7.7321
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
+3.84%
1M Leistung:
+9.34%
6M Leistung:
-20.40%
1J Leistung:
+100.46%
1-Tages-Spanne:
$4.30
$4.53
1-Wochen-Bereich:
$4.095
$4.53
52-Wochen-Spanne:
$2.13
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.33 | 321.57M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Corvus Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable investment returns - jammulinksnews.com
What drives Corvus Pharmaceuticals Inc. stock priceUnmatched market performance - jammulinksnews.com
Is Corvus Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - jammulinksnews.com
What analysts say about Corvus Pharmaceuticals Inc. stockExplosive trading growth - jammulinksnews.com
Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyDouble Your Capital Alerts - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser
Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener
Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks
Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest
OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada
Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus
Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan
Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX
Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha
Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq
Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener
Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia
Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com
Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus
Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India
Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com
Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World
Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):